Screener
Aktis Oncology, Inc. AKTS Q4 2024 earnings
Reported March 30, 2026
Revenue$1.7MMiss by $1.6M
EPS-$1.27Beat by $20.32
Revenue estimate$3.3M
EPS estimate-$21.59
Next report
Date not yet announcedVersus estimates
Revenue
Q3 2026$3.9MMiss by $968.5KQ2 2026$3.4MBeat by $686.3KQ1 2026$3.2MBeat by $997.0K
Q4 2024$1.7MMiss by $1.6M
Q4 2025$4.6MDiluted EPS
Q3 2026-$0.54Miss by $0.07Q2 2026-$0.44Miss by $0.01Q1 2026-$0.38Miss by $0.07
Q4 2024-$1.27Beat by $20.32
Q4 2025-$60.17FAQ
- When did Aktis Oncology, Inc. report Q4 2024 earnings?
- Aktis Oncology, Inc. (AKTS) reported Q4 2024 earnings on March 30, 2026.
- What were Aktis Oncology, Inc.'s Q4 2024 revenue and EPS?
- Aktis Oncology, Inc. reported revenue of $1.7M and eps of $-1.27 for Q4 2024.
- Did Aktis Oncology, Inc. beat estimates in Q4 2024?
- Revenue missed the consensus estimate of $3.3M by $1.6M. EPS beat the consensus estimate of $-21.59 by $20.32.
- Where can I find Aktis Oncology, Inc.'s Q4 2024 SEC filings?
- You can read the 8-K earnings release (0001193125-26-132524) directly on SEC EDGAR. The filing index links above go to sec.gov.
